Tessamorelin

The speaker groups Tessamorelin alongside BPC-157 and Retatrutide as peptides with comparatively less long-term safety data than testosterone. No mechanistic detail, dosage, or protocol information is provided. The claim is rhetorical in nature, intended to challenge longevity-focused marketing of peptides. This reflects the speaker's personal assessment of the evidence landscape.